WINTON GROUP Ltd Takes $1.01 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

WINTON GROUP Ltd acquired a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,665 shares of the company’s stock, valued at approximately $1,006,000.

Several other hedge funds have also recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its holdings in shares of NewAmsterdam Pharma by 96.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after purchasing an additional 845,110 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $2,649,000. SBI Okasan Asset Management Co.Ltd. bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $522,000. Geode Capital Management LLC grew its position in NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after buying an additional 437 shares during the period. Finally, Swedbank AB bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $3,189,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NAMS has been the subject of several recent research reports. Needham & Company LLC boosted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price for the company. Guggenheim boosted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and an average target price of $48.60.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.74% of the stock is currently owned by insiders.

NewAmsterdam Pharma Price Performance

NAMS opened at $30.38 on Wednesday. The firm has a market cap of $3.55 billion, a P/E ratio of -16.97 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21. The company has a 50 day simple moving average of $33.53 and a two-hundred day simple moving average of $33.82.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. Equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.